DiscoverAll Things AmyloidThe Systemic Amyloidoses vs Parkinson’s vs. Alzheimer’s
The Systemic Amyloidoses vs Parkinson’s vs. Alzheimer’s

The Systemic Amyloidoses vs Parkinson’s vs. Alzheimer’s

Update: 2025-10-01
Share

Description

Send us a text

In this episode of All Things Amyloid, we hear from renowned researcher Dr. Jeff Kelly from Scripps Research, pioneer in the field of amyloidosis. Current medical education on amyloid diseases is 25 years old and materially outdated, punctuated by rapid advancement in the last decade. Adapted from his video “The Systemic Amyloidoses vs Parkinson’s vs. Alzheimer’s” hear from Dr. Kelly, developer of ATTR amyloidosis drug Tafamidis, about the current biology and how amyloid diseases such as the Systemic Amyloidoses (ATTR and AL), Parkinson’s and Alzheimer's are today believed to be more similar than different. His video can be found in the Education Hub on Mackenzie’s Mission website. For an overview of amyloidosis, please see episode 2 (for clinicians) or episode 3 (for patients).

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

The Systemic Amyloidoses vs Parkinson’s vs. Alzheimer’s

The Systemic Amyloidoses vs Parkinson’s vs. Alzheimer’s

Mackenzie's Mission